Now that Bristol-Myers Squibb Co. has closed its purchase of Celgene Corp. for nearly $76bn in cash and stock, the big pharma will have to keep up the momentum within its newly acquired pipeline to achieve the value it promised at the start of 2019 when the deal was announced.
The transaction, which initially was valued at $74bn, ended up giving Celgene shareholders an almost $2bn additional return on their investment, thanks to Bristol’s recently rising stock price. The buyer gave Celgene investors $50 in cash and one share of Bristol stock for each share of Celgene that they owned
